UBS AM
MRTX

UBS AM’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

UBS AM’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-65,534
Closed -$3.85M – 2585
2023
Q4 		$3.85M Sell
65,534
-232,660
-78% -$13.1M ﹤0.01% 1375
2023
Q3 		$13M Sell
298,194
-4,627
-2% -$165K 0.01% 870
2023
Q2 		$11.3M Hold
302,821
– – 0.01% 925
2023
Q1 		$11.3M Buy
302,821
+62,919
+26% +$2.83M 0.01% 925
2022
Q4 		$10.9M Buy
239,902
+37,976
+19% +$2.46M 0.01% 910
2022
Q3 		$14.1M Sell
201,926
-15,493
-7% -$1.15M 0.01% 857
2022
Q2 		$14.6M Sell
217,419
-70,241
-24% -$4.47M 0.01% 821
2022
Q1 		$23.7M Sell
287,660
-247,405
-46% -$25.3M 0.01% 799
2021
Q4 		$78.5M Buy
535,065
+128,065
+31% +$19.9M 0.03% 533
2021
Q3 		$72M Sell
407,000
-23,751
-6% -$3.82M 0.03% 539
2021
Q2 		$69.6M Sell
430,751
-33,339
-7% -$5.35M 0.03% 550
2021
Q1 		$79.5M Sell
464,090
-27,926
-6% -$5.53M 0.04% 482
2020
Q4 		$108M Sell
492,016
-154,280
-24% -$33.4M 0.05% 382
2020
Q3 		$107M Buy
646,296
+41,646
+7% +$5.7M 0.06% 321
2020
Q2 		$69M Buy
604,650
+6,187
+1% +$600K 0.04% 400
2020
Q1 		$46M Buy
598,463
+233,931
+64% +$21M 0.03% 462
2019
Q4 		$47M Buy
364,532
+128,939
+55% +$12.4M 0.03% 545
2019
Q3 		$18.4M Buy
235,593
+213,716
+977% +$20.1M 0.01% 786
2019
Q2 		$2.25M Buy
21,877
+11,117
+103% +$865K ﹤0.01% 1532
2019
Q1 		$789K Buy
10,760
+3,880
+56% +$264K ﹤0.01% 1906
2018
Q4 		$292K Sell
6,880
-2,220
-24% -$88.5K ﹤0.01% 2223
2018
Q3 		$429K Buy
9,100
+300
+3% +$16.7K ﹤0.01% 2151
2018
Q2 		$434K Buy
+8,800
New +$332K ﹤0.01% 2158

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS AM's MRTX Position: Q1 2024 in Review

UBS AM sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 65,534 shares — an estimated $3.85M sold.

UBS AM first reported a position in MRTX in Q2 2018 and held it in 23 quarters. The position peaked at $108M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • UBS AM reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • UBS AM sold 65,534 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.85M.
  • UBS AM first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 23 quarters.
  • UBS AM's Mirati Therapeutics, Inc. Common Stock position peaked at $108M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on UBS AM's 13F filing for Q1 2024, filed 15 May 2024.